AI drug discovery firm Enveda raises $311M at $2B valuation

AI-driven biotech Enveda closed a $311 million Series E round at a doubled $2 billion valuation. The company, which starts from evolution-optimized molecules, has three AI-designed drug candidates in clinical trials.

2026-09-25 ~ 2026-09-26 · 2 related posts

• AI biotech Enveda raises $311M, valuation doubles to $2B — emmanuelvivier · 2026-09-25
• AI drug discovery firm Enveda raises $311M Series E — nathanbenaich · 2026-09-26